Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight increase in price, with a notable net inflow of main funds, indicating positive market sentiment despite some outflows from retail investors [1][2]. Financial Performance - As of November 13, 2025, Meihao Medical's stock closed at 22.22 yuan, up by 1.05% with a trading volume of 84,500 hands and a total transaction amount of 185 million yuan [1]. - For the first three quarters of 2025, the company reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, down by 19.25% [3]. - The third quarter of 2025 saw a single-quarter main revenue of 462 million yuan, up by 2.56%, and a net profit of 93.90 million yuan, up by 5.89% [3]. Market Position and Ratios - Meihao Medical's total market capitalization is 12.64 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company's price-to-earnings ratio (P/E) is 45.53, which is lower than the industry average of 60.24, while the price-to-book ratio (P/B) stands at 3.41, also below the industry average of 4.15 [3]. - The gross margin is reported at 39.34%, significantly lower than the industry average of 51.22%, while the net margin is 17.43%, higher than the industry average of 9.57% [3]. Investment Sentiment - Over the past 90 days, 18 institutions have rated the stock, with 16 buy ratings and 2 hold ratings, indicating strong institutional support [4]. - The average target price set by institutions over the last 90 days is 25.20 yuan, suggesting potential upside from the current trading price [4].
股票行情快报：美好医疗（301363）11月13日主力资金净买入802.48万元